Prognosis
J&J Partner Catalent Gets Key U.S. Clearance to Make Vaccine
- Move clears path for release of millions of vaccine doses
- J&J has goal of shots for 20 million Americans by end of March
This article is for subscribers only.
Millions more doses of Johnson & Johnson’s Covid-19 vaccine are expected to be released after U.S. regulators cleared the way for contract manufacturer Catalent Inc. to help produce them.
The Food and Drug Administration has granted emergency-use authorization to Catalent’s facility in Bloomington, Indiana, to make the single-dose vaccine’s active ingredient and ship the filled and finished product, according to the contract manufacturer. Bloomberg was first to report the regulatory clearance before the announcement.